These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 26427840)

  • 21. SILAC for biomarker discovery.
    Dittmar G; Selbach M
    Proteomics Clin Appl; 2015 Apr; 9(3-4):301-6. PubMed ID: 25504673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery.
    deVera IE; Katz JE; Agus DB
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):541-9. PubMed ID: 17147241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes.
    Lacombe J; Azria D; Mange A; Solassol J
    Expert Rev Proteomics; 2013 Feb; 10(1):33-42. PubMed ID: 23414358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue culture-based breast cancer biomarker discovery platform.
    Kulasingam V; Diamandis EP
    Int J Cancer; 2008 Nov; 123(9):2007-12. PubMed ID: 18712711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.
    Hao J; Graham P; Chang L; Ni J; Wasinger V; Beretov J; Deng J; Duan W; Bucci J; Malouf D; Gillatt D; Li Y
    Oncotarget; 2016 Nov; 7(45):74269-74285. PubMed ID: 27708237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging proteomics biomarkers and prostate cancer burden in Africa.
    Adeola HA; Blackburn JM; Rebbeck TR; Zerbini LF
    Oncotarget; 2017 Jun; 8(23):37991-38007. PubMed ID: 28388542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
    Findeisen P; Neumaier M
    Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomics in prostate cancer biomarker discovery.
    Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
    Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biomarker Discovery of Colorectal Cancer Using Membrane Proteins Extracted from Cancer Tissues].
    Tomonaga T; Kume H
    Rinsho Byori; 2015 Mar; 63(3):322-7. PubMed ID: 26524855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach.
    Chang L; Ni J; Beretov J; Wasinger VC; Hao J; Bucci J; Malouf D; Gillatt D; Graham PH; Li Y
    Sci Rep; 2017 Feb; 7():41834. PubMed ID: 28225015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer proteomics.
    Tan HT; Lee YH; Chung MC
    Mass Spectrom Rev; 2012; 31(5):583-605. PubMed ID: 22422534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The progress of proteomic approaches in searching for cancer biomarkers.
    Kočevar N; Hudler P; Komel R
    N Biotechnol; 2013 Mar; 30(3):319-26. PubMed ID: 23165098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The proteomic advantage: label-free quantification of proteins expressed in bovine milk during experimentally induced coliform mastitis.
    Boehmer JL; DeGrasse JA; McFarland MA; Tall EA; Shefcheck KJ; Ward JL; Bannerman DD
    Vet Immunol Immunopathol; 2010 Dec; 138(4):252-66. PubMed ID: 21067814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials.
    Christensen E; Evans KR; Ménard C; Pintilie M; Bristow RG
    Cancer Metastasis Rev; 2008 Sep; 27(3):375-85. PubMed ID: 18427732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of regulatory molecular events and biomarkers using 2D capillary chromatography and mass spectrometry.
    Powell DW; Merchant ML; Link AJ
    Expert Rev Proteomics; 2006 Feb; 3(1):63-74. PubMed ID: 16445351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical proteomics for cancer biomarker discovery and therapeutic targeting.
    Krieg RC; Paweletz CP; Liotta LA; Petricoin EF
    Technol Cancer Res Treat; 2002 Aug; 1(4):263-72. PubMed ID: 12625785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
    Ekegren T; Hanrieder J; Bergquist J
    J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced proteomic technologies for cancer biomarker discovery.
    Wong SC; Chan CM; Ma BB; Lam MY; Choi GC; Au TC; Chan AS; Chan AT
    Expert Rev Proteomics; 2009 Apr; 6(2):123-34. PubMed ID: 19385940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward an integrated pipeline for protein biomarker development.
    Drabovich AP; Martínez-Morillo E; Diamandis EP
    Biochim Biophys Acta; 2015 Jun; 1854(6):677-86. PubMed ID: 25218201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy resistance: identifying universal biomarkers for various human cancers.
    Larionova I; Rakina M; Ivanyuk E; Trushchuk Y; Chernyshova A; Denisov E
    J Cancer Res Clin Oncol; 2022 May; 148(5):1015-1031. PubMed ID: 35113235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.